about
Growth hormone therapy for Prader-willi syndrome: challenges and solutionsThe rehabilitation of children and adolescents with severe or medically complicated obesity: an ISPED expert opinion document.Learning by observation and learning by doing in Prader-Willi syndrome.Altered B cell homeostasis and toll-like receptor 9-driven response in type 1 diabetes carriers of the C1858T PTPN22 allelic variant: implications in the disease pathogenesisFunctional characterization of a novel KCNJ11 in frame mutation-deletion associated with infancy-onset diabetes and a mild form of intermediate DEND: a battle between K(ATP) gain of channel activity and loss of channel expression.Bullying and Victimization in Overweight and Obese Outpatient Children and Adolescents: An Italian Multicentric Study.Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus.Endocrine autoimmunity in Turner syndromeGrowth hormone secretory pattern in non-obese children and adolescents with Prader-Willi syndrome.Disorders of glucose metabolism in Prader-Willi syndrome: Results of a multicenter Italian cohort study.Sleep disordered breathing in patients with Prader-Willi syndrome: A multicenter study.Non-Alcoholic Fatty Liver Disease (NAFLD) in children and adolescents with Prader-Willi Syndrome (PWS).Congenital hypothyroidism due to ectopic sublingual thyroid gland in Prader-Willi Syndrome: a case report.Altered B cell homeostasis and Toll-like receptor 9-driven response in patients affected by autoimmune polyglandular syndrome Type 1: Altered B cell phenotype and dysregulation of the B cell function in APECED patients.Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls.Metabolic syndrome in adult patients with Prader-Willi syndrome.Growth hormone response to standard provocative stimuli and combined tests in very young children with Prader-Willi syndrome.Analysis of the autoimmune regulator gene in patients with autoimmune non-APECED polyendocrinopathies.The GHRH + arginine stimulated pituitary GH secretion in children and adults with Prader-Willi syndrome shows age- and BMI-dependent and genotype-related differences.25OH vitamin D levels in pediatric patients affected by Prader-Willi syndrome.Explorative function in Prader-Willi syndrome analyzed through an ecological spatial task.The Interplay among BMI z-Score, Peer Victmization, and Self-Concept in Outpatient Children and Adolescents with Overweight or Obesity.AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial.Analysis of Circulating Mediators of Bone Remodeling in Prader-Willi Syndrome.GHRH plus arginine and arginine administration evokes the same ratio of GH isoforms levels in young patients with Prader-Willi syndrome.A Next Generation Sequencing custom gene panel as first line diagnostic tool for atypical cases of syndromic obesity: Application in a case of Alström syndrome.Multiple forms of hypogonadism of central, peripheral or combined origin in males with Prader-Willi syndrome.Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of PediatricsComputer use, free time activities and metabolic control in patients with type 1 diabetesIdentification and functional characterization of CD8+ T regulatory cells in type 1 diabetes patientsThyroid function in patients with Prader-Willi syndrome: an Italian multicenter study of 339 patientsUse of GLP-1 receptor agonists in Prader-Willi Syndrome: report of six casesAutoimmune pituitary involvement in Prader-Willi syndrome: new perspective for further researchHigh uric acid, reduced glomerular filtration rate and non-alcoholic fatty liver in young people with obesityAnthropometric characteristics of newborns with Prader-Willi syndromeUniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment
P50
Q26744053-50B4FAE3-5B65-4E1B-A144-30E56C729B5AQ30248211-A208F420-8EAB-4040-8C93-4D6C699FF724Q30643463-CA317315-3AEE-40E3-A578-AE078754A71CQ34380329-4B19A065-3775-4516-946A-592DB6EED18BQ34718408-29D7E0ED-BA46-42A3-8D21-62B7C99AA673Q35852513-2E025A7D-3DB3-4ABF-8F96-52367A0AB473Q36184263-2060B2FC-C003-4557-AEEB-536F5868A13FQ37511962-D5234390-D025-432A-B1BB-81BD83A0B2E0Q39471082-44E2A311-2087-4F70-B8B1-D933040ABC2DQ39628792-9FD8984E-564C-41FB-B556-654C3882098FQ41103661-AA7A8942-7902-4F8D-ADCB-E3ADA860BA22Q41623393-34CEDFB1-A954-4661-8F95-81406B63AA09Q42362951-8C23D02A-3F68-40C4-8D62-BA577B577662Q42498921-93648BA8-7A02-4713-8C78-31BAAAC7AC24Q43416625-64983B6F-B588-4CA2-8940-C19AEE96C5C8Q43429393-8B7E68CE-222C-428B-9F21-A94FE610A858Q44765804-F163A99A-DEAB-47B2-84BA-B9840DCAC9DDQ46003739-06312A78-85B6-4058-B508-7FF535A6035CQ46877560-B0498F4F-EFF9-408C-B681-F724CF1C90A9Q47660361-9C7F4233-A934-49B0-B0BB-B41D2242820FQ47688398-6B487D77-66FF-4589-A4A9-E8C3B47F1688Q47947894-703E9D5C-09D2-40DE-9BE8-D6F12C0DAB3DQ48269619-C999F0F2-B58B-45A9-A159-51C3FB0545C1Q49897946-AEE08C4B-F9FF-494F-A9DE-06D5EEF6FFBDQ50023424-5B55551B-8716-464B-9928-3F8722A7FFF3Q50100314-AB9DB7DD-7897-454A-87AA-B70EF50C6C4EQ53236736-BB9AF0E3-4280-43B9-8290-F4B46BE2CCCBQ56360434-6CB0989A-59CE-49B9-81C6-A851E0E93671Q60167701-A0F5A80A-E400-4B39-803A-34C46D1EA741Q61815764-DB2910BA-55C0-4891-ACA3-FA9C233DABFCQ64040956-C9422802-EFDE-4646-9005-DECC2B38DF47Q87486065-CFF93E87-0EBE-4E2B-857F-9932A6ACF23AQ89397661-A5B53C56-3A9C-4D0D-982C-ED1A32C6FD65Q90866057-8E95F335-3185-442D-9CE8-FA13FFDD0571Q92284789-E2C748B4-25AC-43C5-A9B2-CB40BA29CEC8Q93124797-69B23706-15EA-4CE5-9479-0F8F5F496A8C
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
A Crinò
@en
A Crinò
@nl
type
label
A Crinò
@en
A Crinò
@nl
prefLabel
A Crinò
@en
A Crinò
@nl
P31
P496
0000-0003-3548-7114